Marked Hyperbilirubinemia—Silent No More! - 26/11/20
Doi : 10.1016/j.amjmed.2020.04.031
Vanessa E. Kennedy, MD ⁎ 
, Andrew D. Leavitt, MD, Patricia Cornett, MD
, Andrew D. Leavitt, MD, Patricia Cornett, MD Division of Hematology and Oncology, Department of Medicine, University of California San Francisco Medical Center, San Francisco
⁎Requests for reprints should be addressed to Vanessa E. Kennedy, MD, Division of Hematology and Oncology, Department of Medicine, University of California San Francisco Medical Center, 505 Parnassus Avenue, Room M1286, San Francisco, CA 94143.Division of Hematology and OncologyDepartment of MedicineUniversity of California San Francisco Medical Center505 Parnassus Avenue, Room M1286San FranciscoCA94143
Plan
| Funding: None. |
|
| Conflict of Interest: None. |
|
| Authorship: VEK contributed to conceptualization, writing—original draft, and writing—review and editing. AL and PC contributed to conceptualization and writing—review and editing. All authors had access to the primary patient data. |
© 2020
Elsevier Inc. Tous droits réservés.
Vol 133 - N° 12
P. e733-e734 - décembre 2020 Retour au numéro
Article précédent
- Recurrent Lethal Allergic Coronary Vasospasm
- Mohammed Elzeneini, Seyed Hossein Aalaei-Andabili, Ellen C. Keeley
- Atrial Myxoma Presenting as Atrial Flutter During Sedation for Esophagogastroduodenoscopy
- Rui Zhou, Shuangyue Li, Baoli Cheng, Xiangming Fang
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?